Over the past decade, active surveillance (AS) has increasingly become recognized as the standard of care for patients with Grade Group (GG) 1 prostate cancer (PC).1,2 AS aims to avoid unnecessary radical treatment by monitoring patients using a combination of prostate-specific antigen (PSA) testing, digital rectal examinations (DRE), imaging, and prostate biopsies. This evidence concerns the gene KLK3 and Familial prostate cancer.